There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX), Acelrx (ACRX) and Nucana Plc (NCNA) with bullish sentiments.
Pacira Pharmaceuticals (PCRX)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $85. The company’s shares opened today at $36.28.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -9.4% and a 34.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Pacira Pharmaceuticals is a Hold with an average price target of $50.75, a 39.9% upside from current levels. In a report issued on March 1, H.C. Wainwright also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Acelrx (ACRX)
In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Acelrx, with a price target of $10. The company’s shares opened today at $3.55.
According to TipRanks.com, Higgins ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.7% and a 31.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acelrx with a $8 average price target, which is a 125.4% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.
Nucana Plc (NCNA)
In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Nucana Plc. The company’s shares opened today at $12.17, close to its 52-week low of $10.37.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 4.8% and a 42.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Nucana Plc has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
